Calu-3 / Calu-3-luc Orthotopic Mouse Model Service for Lung Cancer

The Calu-3 / Calu-3-luc orthotopic mouse model of lung cancer grows an ERBB2-driven human adenocarcinoma inside the thoracic cavity, capturing organ-site tumor behavior and thoracic dissemination that subcutaneous flank models miss, with luciferase bioluminescence delivering quantitative, whole-animal readouts from implantation onward. Alfa Cytology delivers this model as a complete preclinical service — covering authenticated HTB-55 banking, Calu-3-luc line qualification, intrathoracic implantation in nude recipients, scheduled in vivo imaging, treatment administration, and endpoints spanning tumor burden, pleural and nodal spread, and histopathology.

Overview of Calu-3 / Calu-3-luc Orthotopic Mouse Model for Lung Cancer

Calu-3 is a human non-small cell lung adenocarcinoma cell line established in 1975 by Jorgen Fogh and Germain Trempe at the Sloan Kettering Institute, from the pleural effusion of a 25-year-old male patient whose lung tumor had already metastasized — and who had received prior chemotherapy with cytoxan, bleomycin, and adriamycin. The line is genetically distinctive: ERBB2 gene amplification produces constitutively active ErbB2/HER2 signaling, while EGFR remains wild-type, KRAS carries a G13D mutation, and TP53 and CDKN2A mutations further shape its biology. That combination translates into defined drug-response behavior — documented sensitivity to the EGFR-directed agents erlotinib and cetuximab — and makes Calu-3 a useful benchmark for dissecting ErbB-family dependence in adenocarcinoma.

Fig 1. ⁶⁸Ga-NOTA-MAL-Cys-MZHER₂:₃₄₂ PET/CT imaging of Calu-3-bearing mice showing specific tracer accumulation in HER2-positive Calu-3 tumors (15.6 %ID/g), successful blocking by unlabeled antibody, favorable biodistribution and positive HER2 immunohistochemistry of Calu-3 tumor sections. (Li, Shu, et al., 2024)

What truly differentiates Calu-3 from most lung cancer lines is how much airway epithelium biology it retains. The cells express CK7, occludin, and E-cadherin, produce abundant CFTR, form tight monolayers with high transepithelial electrical resistance, and model mucin-secreting bronchial submucosa gland function at air-liquid interface — properties that have made the line famous in barrier-physiology, toxicology, and respiratory-virus research, including SARS-CoV-2 propagation. Orthotopically, Calu-3-luc cells are implanted into the thoracic cavity by intrathoracic injection into the lung parenchyma or mediastinal region of nude mice, where they establish locally invasive tumors that grow with the pressure dynamics, stromal contacts, and lymphatic drainage of the genuine lung site. Serial whole-body imaging after D-luciferin administration quantifies thoracic tumor burden and treatment response in vivo, giving this platform an unusual breadth — from ErbB-pathway oncology to inhaled-delivery and lung-microenvironment studies — that few lung models can match.

Cell Line Information: Calu-3 / Calu-3-luc

Calu-3 is one of the most extensively characterized human lung adenocarcinoma lines, bridging oncology and airway-physiology research. Its luciferase derivative carries a stably expressed firefly reporter for in vivo imaging. Core attributes are summarized below.

Our Services

Thoracic surgery is unforgiving — a few microliters of leakage or a millimeter of imprecision can compromise an entire cohort — and the Calu-3-luc orthotopic program is where Alfa Cytology’s surgical discipline shows. Authenticated HTB-55 stocks are expanded at restrained passage, reporter lines are released only after uniform in vitro luminescence is confirmed, and intrathoracic implantation follows written technique with post-injection verification imaging. From that first baseline scan through randomized dosing, serial imaging, and thoracic histopathology, Alfa Cytology runs the whole Calu-3 / Calu-3-luc orthotopic workflow as one continuous, accountable preclinical package.

Workflow of Calu-3 / Calu-3-luc Orthotopic Mouse Model Construction

Building the Calu-3-luc orthotopic model hinges on precise intrathoracic delivery and disciplined imaging around a thoracic tumor that grows in a confined anatomical space. The workflow below follows the standard sequence from cell release to terminal histopathology.

1. Authentication and reporter release: Calu-3 / Calu-3-luc stocks are expanded from authenticated HTB-55 master banks at low passage, mycoplasma-tested, and released only after uniform firefly luciferase expression is confirmed by serial in vitro luminescence assay.
2. Inoculum preparation: Log-phase adherent cultures are trypsinized, washed, counted, and resuspended in sterile DPBS at about 3×10⁶ cells in 100 µL per mouse.
3. Recipient preparation: Female BALB/c nude mice are acclimatized, body-weight stratified, and placed under isoflurane anesthesia with chest disinfection and thermal support.
4. Intrathoracic implantation: A fine needle is advanced at roughly 45 degrees adjacent to the sternum to a shallow depth, and the suspension is delivered into the lung parenchyma or mediastinal region; correct intrathoracic deposition is verified immediately by bioluminescence signal localized to the chest.
5. Recovery and baseline imaging: Animals recover under monitoring, and baseline whole-body imaging after intraperitoneal D-luciferin (150 mg/kg) documents engraftment and starting thoracic photon flux.
6. Serial imaging and randomized treatment: Photon flux is tracked on a fixed schedule alongside body weight and respiratory clinical signs; once signals rise consistently, animals are randomized by matched burden and dosing begins, with erlotinib or cetuximab reference arms available given the line’s documented sensitivity.
7. Terminal workup and histopathology: At endpoint, thoracic tumors are excised and weighed, lungs, mediastinum, and pleural surfaces are inspected and imaged ex vivo, dissemination is scored, and tissues are processed for H&E and marker immunohistochemistry to confirm adenocarcinoma histology and treatment effects.

Fig 2. Calu-3 / Calu-3-luc orthotopic mouse model construction workflow.

Case Study-Calu-3 / Calu-3-luc Orthotopic Mouse Model Development

Alfa Cytology has executed preclinical programs on the Calu-3 orthotopic platform for sponsors advancing ErbB-pathway agents, combination regimens, and lung-targeted delivery systems. In these studies, serial thoracic bioluminescence tracked locally invasive tumor growth and treatment-induced regression over time, baseline-matched randomization balanced arms before dosing, and terminal workups combined tumor weights with ex vivo thoracic imaging and histopathological confirmation of well-differentiated adenocarcinoma. Reference-drug arms informed cross-study comparability where program design called for them, and excised tumors were banked for downstream molecular analysis on request. Study-specific parameters and outcomes are maintained as sponsor-confidential deliverables, and representative outlines can be shared upon request.

Why Choose Alfa Cytology?

A thoracic orthotopic model succeeds or fails on surgical precision and imaging discipline — exactly the combination Alfa Cytology has institutionalized for the Calu-3-luc program. Sponsors choosing this service benefit from:

• Authenticated HTB-55 stocks at restrained passage with verified reporter expression released into studies.
• Written intrathoracic implantation technique with immediate post-injection imaging verification of tumor deposition.
• Fixed-calendar thoracic imaging with signal-matched randomization for balanced treatment arms.
• Optional erlotinib or cetuximab reference arms aligned with the line’s documented ErbB sensitivity.
• Terminal workups covering thoracic dissemination scoring, ex vivo imaging, and adenocarcinoma-confirming histopathology.
• An accountable study team providing per-timepoint visibility from implantation through final report.

Contact Us

Ready to test your program in a thoracic, imaging-quantified lung cancer model? Contact us to discuss implantation route, imaging cadence, and reference-arm options for the Calu-3 / Calu-3-luc orthotopic platform. You can also reach out to Alfa Cytology for a customized study proposal and quotation — our team will respond promptly with a design aligned to your therapeutic strategy.

For research use only. Not intended for any clinical use.